Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 129, Issue 1, 2013, Pages 22-27

  Alvarez, Edwin A ^a,l   Brady, William E ^b   Walker, Joan L ^c   Rotmensch, Jacob ^d   Zhou, Xun C ^e   Kendrick, James E ^f   Yamada, S Diane ^g   Schilder, Jeanne M ^h   Cohn, David E ⁱ   Harrison, Charles R ^j   Moore, Kathleen N ^c   Aghajanian, Carol ^k  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e NEW BRITAIN GENERAL HOSPITAL   (United States)

^f FLORIDA HOSPITAL CANCER INSTITUTE   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h INDIANA UNIVERSITY MEDICAL CENTER   (United States)

ⁱ OHIO STATE UNIVERSITY   (United States)

^j Gynecologic Oncology of West Michigan ^*  (United States)

^k MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Bevacizumab; GOG; Phase II; Recurrent endometrial cancer; Temsirolimus

Indexed keywords

BEVACIZUMAB; TEMSIROLIMUS;

ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; DIGESTIVE SYSTEM FISTULA; DRUG EFFICACY; DRUG FATALITY; EMBOLISM; ENDOCRINE DISEASE; ENDOMETRIUM CARCINOMA; EPISTAXIS; FEMALE; HUMAN; INTESTINE PERFORATION; LEUKOPENIA; LUNG TOXICITY; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEXUAL DYSFUNCTION; SKIN TOXICITY; SMALL INTESTINE OBSTRUCTION; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE; VAGINA DISEASE; VASCULAR DISEASE; VISUAL DISORDER;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SIROLIMUS;

EID: 84875539239     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.12.022     Document Type: Article

References (25)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. G.L. Mutter, M.C. Lin, J.T. Fitzgerald, J.B. Kum, J.P. Baak, and J.A. Lees Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers J Natl Cancer Inst 92 2000 924 930
3. K. Kurose, X.P. Zhou, T. Araki, S.A. Cannistra, E.R. Maher, and C. Eng Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas Am J Pathol 158 2001 2097 2106
4. X. Zhu, C.H. Kwon, P.W. Schlosshauer, L.H. Ellenson, and S.J. Baker PTEN induces G(1) cell cycle arrest and decreases cyclin D3 levels in endometrial carcinoma cells Cancer Res 61 2001 4569 4575
5. A. Sakurada, H. Hamada, S. Fukushige, T. Yokoyama, K. Yoshinaga, and T. Furukawa Adenovirus-mediated delivery of the PTEN gene inhibits cell growth by induction of apoptosis in endometrial cancer Int J Oncol 15 1999 1069 1074
6. K. Oda, D. Stokoe, Y. Taketani, and F. McCormick High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma Cancer Res 65 2005 10669 10673
7. A.M. Oza, L. Elit, M.S. Tsao, S. Kamel-Reid, J. Biagi, and D.M. Provencher Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group J Clin Oncol 29 2001 3278 3285
8. G.F. Fleming, V.L. Filiaci, P. Hanjani, J.J. Burke II, S.A. Davidson, and K.K. Leslie Hormone therapy plus temsirolimus for endometrial carcinoma (EC): Gynecologic Oncology Group trial #248 J Clin Oncol 29 15s 2011 335s [ASCO #5014]
9. C. Aghajanian, M.W. Sill, K.M. Darcy, B. Greer, D.S. McMeekin, and P.G. Rose Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study J Clin Oncol 29 2011 2259 2265
10. J. Merchan, G. Liu, T. Fitch, J. Picus, R. Qin, and H.C. Pitot Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: Phase I safety and activity results J Clin Oncol 25 18S 2007 [ASCO #5034]
11. M.W. Sill, L. Rubinstein, S. Litwin, and G. Yothers A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage phase II clinical trials Clin Trials 9 4 2012 385 395 [August 1]
12. M.H. Einstein, R.M. Wenham, R. Morgan, M.C. Cristea, E.L. Strevel, and A.M. Oza Phase II trial of temsirolimus and bevacizumab for initial recurrence of endometrial cancer J Clin Oncol 30 suppl 2012 [ASCO # 5025]
13. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
14. D.S. McMeekin, M.W. Sill, D. Benbrook, K.M. Darcy, D.J. Stearns-Kurosawa, and L. Eaton A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study Gynecol Oncol 105 2007 508 516
15. A. Giatromanolaki, M.I. Koukourakis, H. Turley, E. Sivridis, A.L. Harris, and K.C. Gatter Phosphorylated KDR expression in endometrial cancer cells relates to HIF1alpha/VEGF pathway and unfavourable prognosis Mod Pathol 19 2006 701 707
16. J. Karar, and A. Maity PI3K/AKT/mTOR pathway in angiogenesis Front Mol Neurosci 4 2011 51
17. N. Colombo, S. McMeekin, P. Schwartz, J. Kostka, C. Sessa, and P. Gehrig A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer J Clin Oncol, ASCO Annual Meeting Proceedings 2007; Part I vol 25, No. 18S (June 20 Supplement) 2007 5516
18. A.M. Oza, A. Poveda, A.R. Clamp, S. Pignata, G. Scambia, and J. Del Campo A randomized phase II (RP2) trial of ridaforolimus (RO) compared with progestin (P) or chemotherapy (C) in female adult patients with advanced endometrial carcinoma J Clin Oncol 29 2001 [Suppl.; abstr 5009]
19. M. Mackay, S. Welch, M.S. Tsao, J.J. Biagi, L. Elit, and P. Ghatage Phase II study of oral ridaforolimus in patients with metastatic and/or locally advanced recurrent endometrial cancer: NCIC CTG IND 192 J Clin Oncol 29 s5013 2011
20. B.M. Slomovitz, K.H. Lu, T. Johnston, R.L. Coleman, M. Munsell, and R.R. Broaddus A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma Cancer 116 2010 5415 5419
21. B.M. Slomovitz, J. Brown, T.A. Johnston, D. Mura, C. Levenback, and J. Wolf A phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma J Clin Oncol 29 s 5012 2011
22. K.K. Ward, N.R. Shah, C.C. Saenz, M.T. McHale, E.A. Alvarez, and S.C. Plaxe Cardiovascular disease is the leading cause of death among endometrial cancer patients Gynecol Oncol 126 2 2012 176 179
23. S. Négrier, G. Gravis, D. Pérol, C. Chevreau, R. Delva, and J.O. Bay Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial Lancet Oncol 12 7 2011 673 680
24. K.A. Margolin, J. Moon, L.E. Flaherty, C.D. Lao, W.L. Akerley 3rd, and M. Othus Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438) Clin Cancer Res 18 4 2012 1129 1137
25. S.M. Ansell, H. Tang, P.J. Kurtin, P.A. Koenig, D.J. Inwards, and K. Shah Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study Lancet Oncol 12 4 2011 361 368